Cell-mediated immunity and antibody responses to Bordetella pertussis antigens in children with a history of pertussis infection and in recipients of an acellular pertussis vaccine

Journal of Infectious Diseases

Volumn 181, Issue 6, 2000, Pages 1989-1995

  Ausiello, Clara Maria ^a   Lande, Roberto ^a   Urbani, Francesca ^a   Di Carlo, Beatrice ^a   Stefanelli, Paola ^a   Salmaso, Stefania ^a   Mastrantonio, Paola ^a   Cassone, Antonio ^a  

^a ISTITUTO SUPERIORE DI SANITÀ   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BACTERIAL ANTIGEN; DIPHTHERIA PERTUSSIS TETANUS VACCINE; DIPHTHERIA TETANUS VACCINE; HEMOGLOBIN; PERTUSSIS TOXIN;

ANTIBODY RESPONSE; ARTICLE; BORDETELLA PERTUSSIS; CELLULAR IMMUNITY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; HUMAN; INFANT; LYMPHOCYTE PROLIFERATION; PERTUSSIS; PRESCHOOL CHILD; PRIORITY JOURNAL; SEROLOGY; VACCINATION;

ANTIBODIES, BACTERIAL; ANTIGENS, BACTERIAL; BORDETELLA PERTUSSIS; CHILD; CHILD, PRESCHOOL; DIPHTHERIA TOXOID; DIPHTHERIA-TETANUS VACCINE; DIPHTHERIA-TETANUS-PERTUSSIS VACCINE; HUMANS; IMMUNITY, CELLULAR; INTERFERON TYPE II; INTERLEUKIN-5; TETANUS TOXOID; VACCINES, COMBINED; WHOOPING COUGH;

EID: 0034131388     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/315509     Document Type: Article

References (38)

1. 1. Hewlett EL. Pertussis: current concepts of pathogenesis and prevention. Pediatr Infect Dis J 1997; 16:S78-84.
2. 2. Strauss E. New clues to whooping cough pathology. Science 1999; 285:81.
3. 3. Flak TA, Goldman WE. Signalling and cellular specificity of airway nitric oxide production in pertussis. Cell Microbiol 1999; 1:51-60.
4. 4. Cherry JD. Comparative efficacy of acellular pertussis vaccines: an analysis of recent trials. Pediatr Infect Dis J 1997; 16:S90-6.
5. 5. Edwards KM, Decher MD. Acellular pertussis vaccines for infants. N Engl J Med 1996; 334:391-2.
6. 6. Guiso N, Capiau C, Carletti G, Poolman J, Hauser P. Intranasal murine model of Bordetella pertussis infection: I. Prediction of protection in human infants by acellular vaccines. Vaccine 1999; 17:2366-76.
7. 7. Mahon BP, Sheanhan BJ, Griffin F, Murphy G, Mills KHG. Atypical disease after B. pertussis respiratory infection of mice with targeted disruptions of interferon-γ receptor or immunoglobulin μ chain genes. J Exp Med 1997; 186:1843-51.
8. 8. McGuirk P, Mahon BP, Griffin F, Mills KHG. Compartmentalization of T cell responses following respiratory infection with B. pertussis: hyporesponsiveness of lung T cells is associated with modulated expression of the co-stimulatory molecule CD28. Eur J Immunol 1998; 28:153-63.
9. 9. Mills KHG, Ryan M, Ryan E, Mahon BP. A murine model in which protection correlates with pertussis vaccine efficacy in children reveals complementary roles for humoral and cell-mediated immunity in protection against B. pertussis. Infect Immun 1998; 66:594-602.
10. 10. Cassone A, Ausiello CM, Urbani F, et al. Cell-mediated and antibody responses to Bordetella pertussis antigens in children vaccinated with acellular or whole-cell pertussis vaccines. Arch Pediatr Adolesc Med 1997; 151:283-9.
11. 11. Ausiello CM, Urbani F, la Sala A, Lande R, Cassone A. Vaccine and antigen-dependent type 1 and type 2 cytokine induction in children after primary vaccination with whole-cell or acellular pertussis vaccines. Infect Immun 1997; 65:2168-74.
12. 12. Zepp F, Knuf M, Habermehl P, et al. Pertussis-specific cell-mediated immunity in infants after vaccination with a tricomponent acellular pertussis vaccine. Infect Immun 1996; 64:4078-84.
13. 13. Ryan M, Murphy G, Nilsson L, et al. Distinct T-cell subtypes induced with whole cell and acellular pertussis vaccines in children. Immunology 1998; 93:1-10.
14. 14. He Q, Tran Minh NN, Edelman K, Viljanen MK, Arvilommi H, Mertsola J. Cytokine mRNA expression and proliferative responses induced by pertussis toxin, filamentous hemagglutinin, and pertactin of Bordetella pertussis in the peripheral blood mononuclear cells of infected and immunized schoolchildren and adults. Infect Immun 1998; 66:3796-801.
15. 15. Ada GL. The immunological principles of vaccination. Lancet 1990; 335: 523-6.
16. 16. Abbas AK, Murphy KM, Sher A. Functional diversity of helper T lymphocytes. Nature 1996; 383:787-93.
17. 17. Fresno M, Kopf M, Rivas L. Cytokines and infectious diseases. Immunol Today 1997; 18:56-8.
18. 18. Cherry JD, Gornbein J, Heininger U, Stehr K. A search for serologic correlates of immunity to Bordetella pertussis cough illnesses. Vaccine 1998; 16: 1901-6.
19. 19. Edwards KM, Meade BD, Decker MD, et al. Comparison of thirteen acellular pertussis vaccines: overview and serological response. Pediatrics 1995; 96:548-57.
20. 20. Giuliano M, Mastrantonio P, Giammanco A, Piscitelli A, Salmaso S, Wassilak SGF. Antibody responses and persistence in the two years after immunization with two acellular vaccines and one whole-cell vaccine against pertussis. J Pediatr 1998; 132:983-8.
21. 21. Storsaeter J, Hallander HO, Gustafsson L, Olin P. Levels of anti-pertussis antibodies related to protection after household exposure to Bordetella pertussis. Vaccine 1998; 16:1907-16.
22. 22. Ausiello CM, Lande R, Urbani F, et al. Cell-mediated immune responses in four-year old children after primary immunization with acellular pertussis vaccines. Infect Immun 1999; 67:4064-71.
23. 23. Ausiello CM, Lande R, la Sala A, Urbani F, Cassone A. Cell-mediated immune response of healthy adults to B. pertussis vaccine antigens. J Infect Dis 1998; 178:466-70.
24. 24. Rota MC, Ausiello CM, D'Amelio R, et al. Prevalence of markers of exposure to Bordetella pertussis among Italian young adults. Clin Infect Dis 1998; 26: 297-302.
25. 25. Greco D, Salmaso S, Mastrantonio P, et al. A controlled trial of two acellular vaccines and one whole-cell vaccine against pertussis. N Engl J Med 1996; 334:341-8.
26. 26. Salmaso S, Mastrantonio P, Wassilak SGF, et al. Persistence of protection through 33 months of age provided by immunization in infancy with two three-component acellular pertussis vaccines. Vaccine 1998; 16:1270-5.
27. 27. Levy-Bruhl D, Pebody R, Veldhuijzen I, Valenciano M, Osborne K. ESEN: a comparison of vaccination programmes. II. pertussis. Eurosurv Wkly 1998; 3:107-10.
28. 28. Schiavo G, Montecucco C. Tetanus and botulism neurotoxins: isolation and assay. Methods Enzymol 1995; 248:643-52.
29. 29. Meade BD, Deforest A, Edwards KM, et al. Description and evaluation of serologic assays used in a multicenter trial of acellular pertussis vaccines. Pediatrics 1995; 96:570-5.
30. 30. Manclark CR, Meade BD, Burstyn DG. Serological response to Bordetella pertussis. In: Rose NR, Friedman H, Fahey JL, eds. Manual of clinical laboratory immunology. 3d ed. Washington, DC: American Society for Microbiology, 1986:388-94.
31. 31. Salmaso S, Tozzi AE, Ciofi degli Atti ML. Observer bias in acellular pertussis vaccine trials. Pediatrics 1999; 104:997-8.
32. 32. Ryan M, Murphy G, Gothefors L, Nilsson L, Storsaeter J, Mills KHG. Bordetella pertussis respiratory infection in children is associated with preferential activation of type 1 T helper cells. J Infect Dis 1997; 175:1246-50.
33. 33. Tran Minh NN, Edelman K, He Q, Viljanen MK, Arvilommi H, Mertsola J. Antibody and cell-mediated immune responses to booster immunization with a new acellular pertussis vaccine in school children. Vaccine 1998; 16:1604-10.
34. 34. Isacson J, Trollfors B, Taranger J, Lagergard T. Acquisition of IgG serum antibodies against two Bordetella antigens (filamentous hemagglutinin and pertactin) in children with no symptoms of pertussis. Pediatr Infect Dis J 1995; 14:517-21.
35. 35. Barenkamp SJ, Leininger E. Cloning, expression, and DNA sequence analysis of genes encoding nontypeable Haemophilus influenzae high-molecular-weight surface-exposed proteins related to filamentous hemagglutinin of Bordetella pertussis. Infect Immun 1992; 60:1302-13.
36. 36. Mooi FR, van der Heide HGJ, TerAvest AR, et al. Characterization of fimbrial subunits from Bordetella species. Microb Pathog 1987; 3:1-8.
37. 37. Tindberg Y, Blennow, Granstrom M. A ten year follow-up after immunization with a two component acellular pertussis vaccine. Pediatr Infect Dis J 1999; 18:361-5.
38. 38. Isacson J, Trollfors B, Taranger J, et al. Safety, immunogenicity and an open, retrospective study of efficacy of a monocomponent pertussis toxoid vaccine in infants. Pediatr Infect Dis J 1994; 13:22-7.